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The generation of insulin-producing β cells from stem
cells in vitro provides a promising source of cells for cell
transplantation therapy in diabetes. However, insulin-
producing cells generated from human stem cells show
deficiency in many functional characteristics compared
with pancreatic β cells. Recent reports have shown
molecular ties between the cell cycle and the
differentiation mechanism of embryonic stem (ES) cells,
assuming that cell fate decisions are controlled by the
cell cycle machinery. Both β cells and ES cells possess
unique cell cycle machinery yet with significant
contrasts. In this review, we compare the cell cycle
control mechanisms in both ES cells and β cells, and
highlight the fundamental differences between
pluripotent cells of embryonic origin and differentiated
β cells. Through critical analysis of the differences of the
cell cycle between these two cell types, we propose
that the cell cycle of ES cells may act as a brake for β-
cell regeneration. Based on these differences, we
discuss the potential of modulating the cell cycle of ES
cells for the large-scale generation of functionally
mature β cells in vitro. Further understanding of the
factors that modulate the ES cell cycle will lead to new
approaches to enhance the production of functional
mature insulin-producing cells, and yield a reliable
system to generate bona fide β cells in vitro.The maintenance of β-cell number and islet mass isBackground
Stem cells are characterized by their prominent capacity
to self-renew and to differentiate into multiple lineages
of cells. Stem cell therapy has the potential to treat in-
tractable disease and to be applied for tissue engineering
and drug screening. Recent strategies in stem cell re-
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been transplanted into animal models with promising re-
sults [2]. One of the rapidly growing diseases that may
be treatable by stem cell therapy is diabetes mellitus
(DM), which affects more than 300 million individuals
worldwide according to the International Diabetes Fed-
eration [3]. Type 1 DM results from autoimmune de-
struction of β cells in the pancreatic islets, whereas the
more common type 2 DM results from peripheral tissue
resistance to insulin, and subsequent β cell dysfunction.
Development of cell therapy for type 1 DM has shown
some success following the Edmonton protocol, in
which diseased islets are replaced by healthy ones from
cadaveric donors [4]. This procedure, however, suffers
many challenges—especially the limited supplies of islets
and their high variability—caused by donor genetic back-
ground and other factors in their isolation [5]. A single
68 kg (150 lb) patient, for example, requires roughly
340–750 million transplanted islet cells to effectively re-
solve type 1 DM [6–8]. In clinical practice, this requires
two or three donors of pancreatic islets for a transplant-
ation procedure into a single patient. Therefore, the gen-
eration of a sufficiently large supply of human β cells
from the same patient’s stem cells could extend stem cell
therapy to millions of new patients suffering from DM.
Additionally, genetically diverse stem cell-derived β cells
could be used for disease modeling either in vitro or
in vivo.
essential to maintaining normoglycemia [9]. In fact, the
production of these insulin-producing cells in adults
often occurs through self-duplication of mature cells in-
stead of differentiation of their stem-cell progenitors
[10–12]. Regardless of the signals required to stimulate
β-cell regeneration, they must all act on the basic cell
cycle replicative machinery. Therefore, analyzing the
pathways that control β-cell regeneration could allow for
novel interventions to introduce a radically new dynamic
to the field of β-cell regeneration. Here, we present per-
spective on the molecular mechanisms that control cellThis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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the potential application of cell cycle modulation for
large-scale production of functional β cells from embry-
onic stem (ES) cells as an effective approach for treat-
ment of DM.
Since the process of stem cell differentiation requires
the coordination of cell cycle progression and cell fate
choices [13–15], we discuss the cell cycle control
mechanisms in ES cells and β cells in the first part of
this review. We then highlight the fundamental differ-
ences between pluripotent cells of embryonic origin
and differentiated β cells. Based on these differences,
we propose that ES cells do not adopt the proper cell
cycle machinery for β-cell regeneration. Modulation of
this unique cell cycle machinery presents a unique
target to develop novel strategies to produce large
numbers of functionally mature insulin-producing cells
in vitro.
The cell cycle of ES cells and pancreatic β cells:
uniqueness and divergence
The use of stem cells in the generation of a renewable
source of β cells remains a realistic promise. However,
many issues still need to be resolved before this strategy
becomes a practical therapeutic option. Although ES
cells seem to have the highest potential to differentiate
into insulin-secreting cells [16], one of the main limita-
tions is the lack of responsiveness to glucose stimulation
[17, 18]. Recent studies have shown, however, that pancre-
atic endoderm cells derived from human ES (hES) cells
can produce insulin in response to glucose several months
after transplantation into immunodeficient mice [19].
Cell cycle regulation in ES cells
Pluripotent cells in the epiblast were shown to have a
cell cycle profile that lacks fully developed G1 and G2
gap phases, in which a longer time (approximately 60 %)
is allocated to the S phase. A similar cell cycle structure
has been described in ES cells [20, 21], which have an
unusual cell cycle structure comprising mainly S phase
cells and a truncated G1 phase [22]. Interestingly,
lengthening the G1 phase by manipulating cell cycle reg-
ulators is sufficient to drive differentiation [23], suggest-
ing that G1 lengthening is a cause rather than a
consequence of differentiation. In hES cells, the cells
reside in S phase 65 % of the time, and in G1 phase only
15 % of the time [24]. Also, the cell cycle of induced
pluripotent stem cells has shown a similar pattern, indi-
cating that rapid division and shortening of the cell cycle
may be crucial for pluripotency [25–27].
The cell cycle represents a tightly regulated process of
cell replication and cell division, and has an important
role in regulation of cell fate decision. The hypothesis
that a link exists between cell cycle regulation and cellfate decisions is supported by the observation that the
essential pluripotency factors OCT4, SOX2, and NANOG
control the expression of key cell cycle regulatory proteins
such as CDK1, cyclin D1, CDK6, CDC7, and CDC25A
[28, 29]. Evidence for another link between cell cycle regu-
lation and self-renewal machinery came from a study by
Chavez and colleagues [30], where E2F was shown to be a
possible regulatory cofactor for OCT4 [30]. Many add-
itional networks are likely to exist between key cell cycle
regulators and stemness, including control via microRNAs
[31]. For instance, the c-Myc/E2F-driven miR-17-92 clus-
ter, which controls the G1–S transition, is fundamental for
hES cell self-renewal and cell proliferation and is de-
creased upon hES cell differentiation [32]. Furthermore,
recent studies have shown that cell cycle regulation is a
rate-limiting step in the process of reprogramming som-
atic cells [33–35]. The reprogramming factor KLF4 was
found to likely function by suppression of p53 [36]. An-
other factor, LIN28, a positive regulator of cyclin A, cyclin
B, and CDK4 [37], was found to improve reprogramming
efficiency [38] by accelerating cell division [39]. Together
these studies show a strong possibility of reprogram-
ming somatic cells by inducing ES cell-specific cell cycle
characteristics. Furthermore, a direct relationship be-
tween cell cycle regulation and pluripotency of ES cells
has been shown, by linking Oct4-regulating genes to
cell cycle progression [40]. Inhibition of Oct4 prompted
downregulation of genes involved in ES cell prolifera-
tion, and an upregulation in the cell cycle inhibitor p21
and expression of p63, all of which have been linked to
differentiation [41].
Although Cdk2 is considered the principal Cdk in hES
cells [20, 42], Cdk4–cyclin D2 complexes have shown lit-
tle activity in murine ES (mES) cells [22, 25, 43]. Rapid
progression of the cell cycle in mES cells was shown to
be due to an unusually high Cdk2 activity in undifferen-
tiated ES cells which is not under the control of the cell
cycle [20]. This high level of Cdk2 activity is due to the
continuous expression of both cyclin E and cyclin A dur-
ing the cell cycle of mES cells [20]. Predictably, inhibition
of Cdk2 activity with the Cdk2 inhibitor Olomoucine II
was shown to restrain mES cell proliferation by keeping
the cells in the G1 phase and preventing G1–S transition
without affecting ES cell pluripotency [44].
In hES cells, knockdown of CDK2 activity was
shown to delay the G1–S transition and cause G1 ar-
rest [45, 46]. Similarly, CDK2 activity was also crucial for
cell fate decisions in hES cells [46, 47]. Similar to mES
cells, hES cells do not express CDK inhibitory proteins of
the Ink4 and Cip/Kip families [22, 48]; therefore, CDKs
have very high activity, with CDK2 showing the overall
highest kinase activity in hES cells [45], indicating a crit-
ical role for CDK2 in G1 phase regulation in both mES
cells and hES cells.
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press any of the D-type cyclins. Moreover, they demon-
strated that 100 % of hES cells were positive for cyclin
E1 protein, suggesting that cyclin E1 is substantially
expressed in undifferentiated hES cells, as is the case
with mES cells [50, 51]. Neganova et al. [45] compared
the expression of all major cyclins in undifferentiated
hES cells and in hES cells that were differentiated into
embryoid bodies. They showed that cyclins E1, A2, and
B1 vacillated during the cell cycle, and undifferentiated
hES cells expressed only cyclins D1 and D3, while the
level of cyclin D2 was very low or undetectable [45].
Cyclin E on the other hand was shown to be involved in
maintaining the pluripotent state of ES cells [50, 51].
Overexpression of cyclin E supported ES cell self-
renewal, and increased the resistance of ES cells to tran-
sient leukemia inhibitory factor withdrawal. However,
loss of cyclin E1 expression in ES cells elongated G1
phase and induced differentiation [52].
Cell cycle regulation in pancreatic β cells
The replication of β cells is regulated by a network of
tightly orchestrated cell cycle regulators. The expression
of these regulators corresponds to the ability of β cells
to replicate at different life stages [53–56]. Cell cycle
progression in murine islets is controlled by three types
of D cyclins (D1, D2 and D3), which bind to and activate
CDK4. As molecular oncologists interested in overall
cell replication, these investigators generated mice that
lack Cdk-4, and predicted a generalized decline in cell
proliferation rates. Interestingly, the data revealed that
global Cdk-4 deletion led to a very restricted phenotype
as Cdk-4 knockout mice showed abnormalities in only
three tissues—ovary, testis, and pancreatic β cells [57, 58].
Pancreatic islets showed cell hypoplasia, which resulted
in diabetes and ketoacidosis [58]. These findings would
seem to indicate a marked specificity of the effect of
the Cdk-4–cyclin D pathway on the cell cycle in β
cells, but they fail to demonstrate why or how it is so
tissue-specific [58]. Furthermore, the adenoviral deliv-
ery of CDK4 into human and rat β cells did increase
β-cell proliferation rates, which were even further in-
creased by cyclin D1 [59]. Moreover, Sertad1 (Sei1),
which helps stabilize the CDK4–cyclin D complex by
hindering p16 binding, thereby advancing cell cycle
progression [60], is expressed at significantly high levels in
pancreatic islets. In fact, Sei1-null mice present mild de-
fects in the islets [60]. Lastly, after partial pancreatectomy,
mice expressing an active Cdk4R24C/R24C kinase had higher
β-cell mass compared with wild type due to elevated levels
of β-cell proliferation in the mutant mice, though not ne-
cessarily at an accelerated pace [61]. Taken together, these
studies show that regulation of Cdk4 is critical to the
maintenance of β-cell replication.Cyclin D1 and D2 are expressed in pancreatic islets,
the latter at higher levels [62]. As β-cell replication di-
minishes with age, so do the expression levels of cyclin
D1 and D2 [63]. Cyclin D2, although not needed for
neonatal development, is critical for controlling β-cell
growth and replication [62]. Cyclin D1 partially compen-
sates for the absence of cyclin D2, since the double mu-
tant aggravates this phenotype, with uncontrollable
diabetes leading to death at an early age [62]. These
studies highlight the importance of cyclin D in regulat-
ing and controlling β-cell proliferation and islet mass.
Consistent with the concept that increased cyclin D ex-
pression causes higher replication rates, adenoviral-
mediated expression of cyclin D1 in both human and
murine islet cells causes increased proliferation [59].
Subsequent to this finding, Daniel Chung and colleagues
[64] overexpressed cyclin D1 in murine islets in vivo and
showed an exceptional increase in islet mass without
hypoglycemia, proposing β-cell replication as the cause
of the islet hyperplasia. Interestingly, the β-cell-specific
overexpression of cyclin D1 did not cause hypoglycemia;
in fact, glucose and insulin levels remained similar to
those in the wild type [64]. Collectively, these studies
provide direct evidence that deletion of cyclin D from
the murine islet stops the cell cycle, diminishing β-cell
proliferation rates. Meanwhile, overexpressing cyclin Ds
in β cells causes increased proliferation through over-
active cell cycle progression.
Comparison of the cell cycle in ES cells and β cells
Both ES cells and β cells have unique cell cycle machin-
eries that exhibit significant differences from each other
(Table 1). ES cells have an unusual cell cycle, comprising
mainly an S phase and a short G1 phase [22] (Fig. 1). Re-
garding the CDKs, Cdk4–cyclin D2 complexes have very
limited activity in ES cells [22, 25, 43], where Cdk2 is
considered the principal Cdk [20, 42]. Interestingly,
Cdk4 is highly expressed in β cells and is not just an im-
portant regulator for cell cycle progression but is also
critical for β-cell development [57, 58]. However, Cdk2
has very limited activity in β cells.
Regarding the cyclins, it has been shown that ES cells
do not express any of the D-type cyclins [49]. However,
100 % of hES cells were positive for cyclin E1 protein,
which is presumably constitutively expressed in both un-
differentiated hES cells and mES cells [50, 51]. In contrast
to other cell types where D-type cyclin-dependent kinases
are not essential for cell cycle entry [65], cyclins D1 and
D2 are critical for β-cell development, where they are
highly expressed in G1 phase. They control the activity of
CDK4/6 that inhibits retinoblastoma protein (pRB)
phosphorylation and frees E2F to start the G1–S tran-
sition. In contrast, cyclin Ds are expressed at low levels
in ES cells with very low activity of CDK4, whereas
Table 1 Differences between the cell cycle machinery of β cells and ES cells
Cell cycle machinery Beta cells ES cells References
Cdk2 Expressed but no functional importance Critical for ES cell maintenance and considered the
primary Cdk
[20, 42, 85]
Cdk4 Critical for β-cell development Not expressed in ES cells [22, 25, 43, 57, 58]
Cdk6 Not expressed Expressed at high levels [22, 86]
Cyclin D1 Expressed at high levels Expressed at low levels [62]
Cyclin D2 Critical for development and highly expressed Not expressed in ES cells [62, 63]
Cyclin E Expressed but no importance Critical for maintaining the pluripotent state of ES cells [50, 51, 87, 88]
ES embryonic stem
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E, bypassing the need of a G1 checkpoint (Fig. 2). Fur-
thermore, the pluripotency of ES cells relies on CDK2
activity.
Therefore, the Cdk4–cyclin D2 complex that is critical
for β-cell development and replication has very limited
activity in ES cells, with undetectable levels of cyclin D2.
It is thus highly likely that the unique cell cycle machin-
ery of ES cells does not support the generation of β cells,
which may provide a plausible explanation for the diffi-
culty in generating functional β cells from them in large
quantities.
Do ES cells adopt the proper cell cycle machinery
for β-cell differentiation?
Murine studies demonstrated that cyclin Ds are expressed
in a tissue-specific manner during gastrulation in the
mouse embryo. For example, the mesoderm expressesFig. 1 Differences in the cell cycle machinery of β cells (a) and undifferentiate
relative to that of β cells. An abbreviated G1 phase is responsible for the diffe
mitogen-activated protein kinase (MAPK) pathway activates CDK4–cyclin D kin
which then leads to release of E2F, allowing it to activate transcription of gen
signaling through the MAPK pathway seems to be irrelevant in the progressio
constitutively active throughout the cell cycle, which allows the transition of E
cyclin D-dependent early G1 phase shortens the G1 phase and the entire cell
absent, making the cell cycle between these two cells highly differentcyclin D1/D2, the neuroectoderm expresses cyclin D1/D2,
and the endoderm expresses a low level of cyclin D2,
whereas cyclin D3 is specifically expressed in the troph-
ectoderm. These studies provided the first evidence for an
interconnection between cell fate decision and cell cycle
regulation. Growth and maintenance of adult β-cell mass
represents a unique model for G1 cell cycle biology. The
expansion of β-cell mass in adults seems to be crucially
dependent on mitogenic signals acting via D-type cyclin/
Cdk4 activity (Fig. 1) [66]. A clear observation of this
phenomenon was shown when the whole body deletion of
Cdk4 in mice specifically restricted β cell proliferation
[58]. It has been shown that one of the D-type cyclins,
cyclin D2, is uniquely required for β-cell replication and
the proper replication of β-cell mass during postnatal de-
velopment. Cyclin D2 thus seems to have a critical role
within β cells in mediating mitogenic stimuli to control β-
cell mass in the pancreas [67].d embryonic stem (ES) cells (b). The cell cycle of ES cells is shortened
rence in cell cycle length. a In β cells, mitogen signaling through the
ase activity, thus hypophosphorylating retinoblastoma protein (pRB),
es necessary in the progression of the cell cycle. b In ES cells, mitogen
n of cell cycle. Cyclin E–CDK2 expression is cell cycle-independent and
S cells from M phase directly to late G1. The resulting absence of the
cycle. In beta cells, cyclin D–CDK4 is highly active but cyclin E–CDK2 is
Fig. 2 Cell cycle regulation of ES cells (a) and β cells (b). Upregulated components are indicated in red and inhibited proteins are indicated in
blue. Levels of the Polycomb protein enhancer of zeste homologue 2 (EZH2) are increased during cell proliferation, which leads to a decrease in
levels of the cell cycle inhibitors p21 and p16INK4A. a In ES cells, Cdk2–cyclin E is considered the primary cell cycle complex and, once activated, it
phosphorylates retinoblastoma protein (pRB). Once pRB has been phosphorylated, E2F is released. The released E2F is then free to act as a transcription
factor and it subsequently binds to DNA promoter regions and activates the expression of proteins required in the next stages of the cell cycle and in
DNA replication. b In β cells, Cdk4–cyclin D is considered the primary cell cycle complex and is responsible for pRb phosphorylation
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hES cells in vitro have only succeeded, to date, in gener-
ating cells with abnormal or immature phenotypes [68].
For example, these cells either fail to respond to
glucose-induced insulin expression in vitro or fail to ex-
press appropriate β-cell markers, such as NKX6-1 or
PDX1. They also abnormally coexpress different hor-
mones, such as glucagon along with insulin, fail to func-
tion after transplantation in vivo, or show a combination
of these abnormal properties [69–73]. These abnormal-
ities may be accounted for by the unique physiological
cell cycle machinery of ES cells, which do not adopt the
proper cell cycle mechanisms necessary for generating
functionally mature β cells. Of special importance is the
Cdk4–cyclin D complex, which is critical for β-cell gen-
eration, and is not present in ES cells.
The Cdk4–cyclin D2 pathway has been suggested to
have different roles in β-cell function, in addition to the
control of cell proliferation, since it is robustly expressed
in non-proliferating β cells [74]. First, Cdk4 directly reg-
ulates expression of Kir6.2, which is a key component of
the KATP channel involved in the regulation of glucose-
induced insulin secretion [74]. Consistently, inhibition
or genetic inactivation of CDK4 results in decreased ex-
pression of Kir6.2, impaired insulin secretion and glu-
cose intolerance in mice [74]. Second, Cdk4 is essential
in regulating early pancreas development and promotes
β-cell mass expansion via activation of Pdx1 and Ngn3
expression [75]. Third, Cdk4 deficiency specifically re-
duces embryonic pancreas size owing to fewer Pdx1+
pancreatic progenitor cells. Additionally, the expression
of activated Cdk4R24C kinase leads to increased Nkx2.2+and Nkx6.1+ cells and also leads to a rise in the number
and proliferation of Ngn3+ endocrine precursors, result-
ing in expansion of the β-cell lineage [75]. Forth, Cdk4
catalyzes the recruitment of quiescent cells within the is-
lets and the ductal epithelium to participate in the re-
generative process [61]. Altogether, it is clear that while
the Cdk4–cyclin D2 complex is critical for β-cell devel-
opment and replication, it has very limited activity in ES
cells, given their undetectable levels of cyclin D2. This
may present a possible explanation for the failure to pro-
duce functional β cells from ES cells on a large scale.
This can also explain the lengthy period of several
months currently required for β-cell differentiation from
ES cells.
While these differences in the cell cycle machinery be-
tween β cells and ES cells may constitute challenges to
current stem cell differentiation protocols, they can also
be viewed as opportunities for further studies in regulat-
ing the cell cycle machinery of ES cells to mimic the ma-
chinery required for large-scale production of functional
β cells in vitro. However, more research is needed to de-
termine the extent to which the cell cycle of ES cells
might contribute to β-cell regeneration, and to establish
a causal link between the cell cycle machinery and β-cell
regeneration from ES cells.
The potential of regulating the cell cycle of ES cells
to ensure large-scale production of functional
β cells
The generation of adult β cells takes place mostly
through self-replication instead of differentiation from
stem cell progenitors; therefore, the cell cycle plays a
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achieve large-scale production of functional β cells from
ES cells, regulating the cell cycle machinery of ES cells
seems to be a worthwhile direction. Since β cells are
now known to be among the most slowly replicating
cells in the body, and because of their unique cell cycle
machinery, special modulation of ES cells may be neces-
sary to achieve effective differentiation.
Pauklin and Vallier [14] have shown that the cell fate
decision is tightly linked to the cell cycle machinery, and
proposed a few mechanisms that synchronize differenti-
ation and proliferation in developing tissues. They also
demonstrated that cell cycle manipulation using a small
molecule directs differentiation of human pluripotent
stem cells, and thus provides an approach to generate
cell types of clinical interest. This led to the suggestion
that simple manipulation of the cell cycle using small
molecules could direct differentiation of pluripotent
stem cells towards particular cell types without the need
for exogenous growth factors [14].
Remarkably, in a recent study by Chen et al. [76],
complete regeneration of pancreatic islets and improve-
ment of streptozotocin-induced diabetes in rats was
achieved following gene therapy with Cdk4–cyclin D2
plasmids. The study reported that this plasmid gene ther-
apy did not result in activation of oncogenes [76], and that
β-cell regeneration was not mediated by self-replication of
pre-existing β cells. Instead, Cdk4–cyclin D2 initiated ac-
tive proliferation of adult pancreatic progenitor cells that
existed within the islets [76]. Since the efficiency of ES
cells to differentiate into tissue-specific cells is influenced
by their cell cycle [14], modulating the cell cycle machin-
ery of ES cells by transient overexpression of the Cdk4–
cyclin D2 complex prior to β-cell differentiation protocols
seems to be an attractive direction, and may open the gate
for generating large numbers of functional β cells within a
short time (Fig. 3).Fig. 3 Proposed differentiation models. a Embryonic stem (ES) cells can dif
b Modulating the cell cycle machinery of ES cells by transient overexpression
may seem to be an attractive direction for the large-scale generation of functConsiderable work still remains to be done to com-
pletely understand the role of the cell cycle machinery of
ES cells in their differentiation into functional β cells. A
growing body of knowledge suggests that manipulation
of the cell cycle and controlled regulation of its various
phases may represent a fundamental and novel approach
to the generation of large numbers of β cells. Developing
novel strategies to precisely control progenitor cell dif-
ferentiation will significantly benefit from studying the
mechanisms that control the relationship between the
ES cell cycle and β-cell regeneration. The time is ripe for
such studies to leverage the growing knowledge about
cell cycle regulation for translational research.Conclusion and perspectives
The generation of large numbers of β cells from hES
cells was recently possible by using specified genes and
signals that were based on studies of pancreatic develop-
ment [77–79]. Endoderm and derived pancreatic pro-
genitors can now be differentiated with high efficiencies
[19, 70, 80]. These cells can differentiate into functional
β cells within 3–4 months following transplantation into
rats [19, 80], demonstrating that a few cells in the prep-
aration contain the developmental capacity to generate β
cells when given enough time and proper cues. Unfortu-
nately, the reason why it takes several months for the
cell differentiation in vivo is not fully understood. Fur-
thermore, there is no evidence that comparable in vivo
differentiation into β cells would apply to human pa-
tients. To date, approaches that include pancrease trans-
plantation, islet cell transplantation, and administration
of anti-CD3 monoclonal antibody have been approved
for clinical therapy of DM [81–83]; however, these pro-
cedures suffer many challenges, especially the limited
supply of islets and their high variability, caused by
donor genetic background and other factors in theirferentiate into functional β cells within 3–4 months in small numbers.
of the CDK4–cyclin D2 complex prior to β-cell differentiation protocols
ionally mature β cells in less time
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for new sources of insulin-producing cells.
Both hES and mES cells have been reported to have
cell cycle features that are more characteristic of somatic
cycling cells [84]. Li et al. [13] showed that molecular
pathways controlling the cell cycle could be engineered
to basically affect ES cell differentiation at early stages
in vitro. Strategies based on modulating these pathways
can shorten the rate and simplify the lineage path of ES
differentiation [13]. This makes it likely that pathways
involving cell proliferation interact at different points
with pathways that control cell lineages in embryos, and
demonstrates that this knowledge can be used product-
ively to guide the path and efficiency of cell differenti-
ation of pluripotent cells.
Both β cells and ES cells have very unique cell cycle
machineries but with a large difference. Cdk4 and its
binding partner, cyclin D2, seem to be critical in β-cell
development. In contrast, ES cells have very limited
Cdk4–cyclin D2 activity, where Cdk2–cyclin E is consid-
ered the primary cell cycle complex. Accordingly, ES
cells do not have the Cdk4 and the cyclin D2 that is crit-
ical for β-cell regeneration. This might be a possible ex-
planation for the difficulty in generating functional β
cells in large quantities from them.
Through critical analysis of the differences of the cell
cycle between these two cells, we propose that the cell
cycle of ES cells may act as a brake for β-cell regener-
ation from ES cells and that their unique cell cycle ma-
chinery may be a possible cause for the generation of β
cells with abnormal or immature phenotypes. This may
also explain the several month-long process of β cell dif-
ferentiation from ES cells. It is possible, therefore, that
the unique differences between the cell cycle machiner-
ies of β cells and ES cells constitute some form of barrier
for generating functional mature β cells from ES cells.
However, understanding these differences should lead to
new strategies for modulating the cell cycle of ES cells
to favor the generation of functional β cells.
Emerging data suggest that there are several links be-
tween basic cell cycle mechanisms and the capacity to
drive ES cells to differentiate into a desired lineage; in
this case, β cells. Based on our hypothesis that the cell
cycle may act as a brake for β-cell regeneration from ES
cells, we propose that modulating the cell cycle machin-
ery of ES cells prior to β-cell differentiation protocols
may present opportunities for the development of revo-
lutionary therapies for diabetes and its complications.
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